ImmunoCult-ACF DC Diff Supplement

A serum-free and animal component-free supplement supplied by STEMCELL Technologies, this reagent supports the differentiation of human monocytes into dendritic cells (DCs) as part of the ImmunoCult™-ACF Dendritic Cell workflow. It is combined with ImmunoCult™-ACF Dendritic Cell Medium and, on day 5, the ImmunoCult™ Dendritic Cell Maturation Supplement to produce fully mature DCs by day 7. Monocytes are cultured at 1 x 10⁶ cells/mL; the medium with differentiation supplement is replaced at day 3, and at day 5 maturation supplement is added directly to the culture without changing the medium.

Published data from the manufacturer show that on day 7, 93 ± 5% of cells expressed the mature DC marker CD83 while only 1 ± 1% retained the monocyte marker CD14, with a viable mature DC yield of 45 ± 25% (mean ± SD, n=39). Supernatant IL-12p70 concentrations reached 361 ± 81 pg/mL for mature DCs versus 5 ± 2 pg/mL for immature DCs (mean ± SEM, n=27). Mature DCs generated with the ImmunoCult™-ACF system induce proliferation of both allogeneic and antigen-specific T cells when primed with the CEF peptide pool (HLA Class I peptides from Cytomegalovirus, Epstein-Barr Virus and Influenza Virus), supporting downstream research in cancer immunotherapy, vaccines and infectious disease.

The ready-to-use, optimized and defined formulation can be used on its own or combined with the matching medium and maturation supplement to suit individual workflows. The product is supplied as a clear liquid, is for research use only, and is not classified as a hazardous substance or mixture under the Globally Harmonized System (GHS) or the 2012 OSHA Hazard Communication Standard.